Sharenet Sites 
Sharenet Sites
Notification in terms of Section 122(3) of the Companies Act and Section 3.83(b) of the JSE Listings Requirements
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
NOTIFICATION IN TERMS OF SECTION 122(3) OF THE COMPANIES ACT AND
SECTION 3.83(b) OF THE JSE LISTINGS REQUIREMENTS
Shareholders are referred to the SENS announcement released by the Company on 29
September 2016 wherein it was confirmed that GlaxoSmithKline (“GSK”) had announced the
disposal of half of its remaining shareholding in Aspen (28.2 million ordinary shares or 6.2% of the
Company’s issued share capital).
In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (“the Act”) and section
3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised
that GSK has now formally provided Aspen with the required notice in terms of section 122(1)(a) of
the Act. This notice confirms that GSK has disposed of 28.2 million ordinary Aspen shares and
that, as a result, it no longer holds any shares in the Company.
Aspen will file the required notice with the Takeover Regulation Panel as required in terms of
section 122(3)(a) of the Act.
Durban
5 October 2016
Sponsor
Investec Bank Limited
About Aspen
Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an
extensive basket of products that provide treatment for a broad spectrum of acute and chronic
conditions experienced through all stages of life. Aspen continues to increase the number of lives
benefitting from its products, reaching more than 150 countries.
Aspen has a strong presence in both emerging and developed countries. Its emerging market
footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the
Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a
developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and
has a growing presence in other developed countries, most notably in Western Europe.
Aspen operates with an established business presence in approximately 50 countries spanning 6
continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities
across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent
global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities
are scalable to demand and cover a wide variety of product-types including oral solid dose, liquids,
semi-solids, steriles, biologicals, APIs and infant nutritionals.
Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed
companies on this exchange. For more information visit: http://www.aspenpharma.com/
Date: 05/10/2016 08:45:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
